Company / Operating Income
Entrada Therapeutics, Inc. Operating Income History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$47.0M
FY2025
5-year range
-$97.2M / $47.0M
FY2023-FY2025
Trend
+1586.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income changed +1587% YoY in FY2025, a notable deviation from the 2-year average annual change of +842%.
Based on SEC 10-K filings.
$47M in FY2025.
Improved from -$97M to $47M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income increased 1586.7% year-over-year.
Company context
Key Data Points
- Altman Z-Score -2.03 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $47.0M | +1586.7% |
| FY2024 | -$3.2M | +96.7% |
| FY2023 | -$97.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026